Mountain View, CA, July 24, 2003
A five-year, $5.3 million agreement to provide additional software
and services—including support for proton therapy—was reached by
The University of Texas M. D. Anderson Cancer Center (M. D.
Anderson) and IMPAC Medical Systems, Inc. (NASDAQ:IMPC), a leading
provider of information management solutions for cancer care.
IMPAC will provide the additional software and services for M. D.
Anderson’s radiation therapy center, satellite facilities, as well
as for M. D. Anderson’s new ambulatory care facility and proton
therapy center.
“This is a collaborative development effort aimed at improving the
process of managing increasingly complex cancer treatment
techniques,” stated Joseph K. Jachinowski, President and CEO of
IMPAC. “IMPAC is delighted to team with M. D. Anderson Cancer
Center in its expansion of the oncology information system to
include support for proton therapy and its new ambulatory care
facility,” he added.
According to James Cox, M.D., head of the Division of Radiation
Oncology at M. D. Anderson, the organization is anticipating the
expansion of IMPAC functionality at the existing facility, as well
as complete implementation of IMPAC systems at the new ambulatory
care facility and the Proton Therapy Center currently under
construction. “IMPAC has consistently provided the Division of
Radiation Oncology with high quality information systems to manage
the operation of our busy cancer center. The expansion of the
system to include support for additional treatment facilities and
our new proton center will help us to further enhance our process
efficiency while maintaining the highest levels of quality across
our entire campus,” he said.
“This agreement solidifies M. D. Anderson’s relationship with
IMPAC as we move forward with our expansion into new modalities
such as proton therapy,” said Mitch Latinkic, Division
Administrator of Radiation Oncology. “IMPAC and M. D. Anderson
have worked closely together since 1995 towards the realization of
our shared vision of the information infrastructure required for
providing leading edge, quality patient care.”
M. D. Anderson is currently comprised of three treatment
facilities and manages over 600 patient visits a day. IMPAC
provides M. D. Anderson’s Radiation Oncology Division with
integrated clinical and administrative management software
comprised of an image-enabled electronic medical record, treatment
and planning device integration, IMRT treatment management and
quality assurance functions, patient registration, scheduling, and
charge capture, all implemented in a wide area network including
wireless connectivity.
About IMPAC Medical Systems, Inc.
IMPAC Medical Systems, Inc. is a leading provider of specialized
IT solutions that streamline both clinical and business operations
to help improve the process of delivering quality patient care.
With open integration to multiple healthcare data and imaging
systems, IMPAC offers a comprehensive IT solution that includes
specialized electronic charting, full-featured practice
management, clinical laboratory management, and outcomes
reporting. Supporting over 1500 installations worldwide, IMPAC
delivers practical solutions that deliver better overall
communication, process efficiency and quality patient care. For
more information about IMPAC Medical Systems’ products and
services, please call 650-623-8800 or visit
www.impac.com.
About M. D. Anderson Cancer Center
M. D. Anderson Cancer Center, located in Houston, was designated
by the National Cancer Institute as one of the first three
Comprehensive Cancer Centers in the United States. The facility is
ranked as the nation’s top cancer hospital in the current issue of
U.S. News and World Report in the “America’s Best Hospitals”
survey, and has consistently ranked in the top two since the
magazine began ranking in 1990. M. D. Anderson has provided care
for more than 520,000 cancer patients since 1944.
The statements contained in this press
release that are not purely historical are forward looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, including statements regarding the Company's
expectations, beliefs, hopes, intentions or strategies regarding
the future. Forward looking statements include statements
regarding the Company's business strategy, timing of, and plans
for, the introduction of new products and enhancements, future
sales, market growth and direction, competition, market share,
revenue growth, operating margins and profitability. All forward
looking statements included in this document are based upon
information available to the Company as of the date hereof, and
the Company assumes no obligation to update any such forward
looking statement. Actual results could differ materially from the
Company's current expectations. Factors that could cause or
contribute to such differences include the Company's ability to
expand outside the radiation oncology market or expand into
international markets, integrate its products successfully with
related products and systems in the medical services industry,
reliance on distributors and manufacturers of oncology equipment
to market its products, and other factors and risks discussed in
the Company's Final Prospectus dated May 12, 2003 and other
reports filed by the Company from time to time with the Securities
and Exchange Commission. |
